{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:25:01Z","timestamp":1793316301743,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Natural Science Foundation of Jilin Province","award":["20200201417JC"],"award-info":[{"award-number":["20200201417JC"]}]},{"name":"the Natural Science Foundation of Jilin Province","award":["20200201417JC"],"award-info":[{"award-number":["20200201417JC"]}]},{"name":"the translation-clinical joint foundation of the First Hospital of Jilin University","award":["No. 2020-ZL-04"],"award-info":[{"award-number":["No. 2020-ZL-04"]}],"id":[{"id":"https:\/\/ror.org\/034haf133","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the translation-clinical joint foundation of the First Hospital of Jilin University","award":["No. 2020-ZL-04"],"award-info":[{"award-number":["No. 2020-ZL-04"]}],"id":[{"id":"https:\/\/ror.org\/034haf133","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Eagle\u2019s Telethon Post-Doctoral Fellowship","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Resistance to targeted therapies represents a significant hurdle to successfully treating hepatocellular carcinoma (HCC). While epigenetic abnormalities are critical determinants of HCC relapse and therapeutic resistance, the underlying mechanisms are poorly understood. We aimed to address whether and how dysregulated epigenetic regulators have regulatory and functional communications in establishing and maintaining drug resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>HCC-resistant cells were characterized by CCK-8, IncuCyte Live-Cell analysis, flow cytometry and wound-healing assays. Target expression was assessed by qPCR and Western blotting. Global and promoter DNA methylation was measured by dotblotting, methylated-DNA immunoprecipitation and enzymatic digestion. Protein interaction and promoter binding of DNMT3a-TET2 were investigated by co-immunoprecipitation, ChIP-qPCR. The regulatory and functional roles of DNMT3a and TET2 were studied by lentivirus infection and puromycin selection. The association of DNMT and TET expression with drug response and survival of HCC patients was assessed by public datasets, spearman correlation coefficients and online tools.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified the coordination of DNMT3a and TET2 as an actionable mechanism of drug resistance in HCC. The faster growth and migration of resistant HCC cells were attributed to DNMT3a and TET2 upregulation followed by increased 5mC and 5hmC production. HCC patients with higher DNMT3a and TET2 had a shorter survival time with a less favorable response to sorafenib therapy than those with lower expression. Cancer stem cell-like cells (CSCs) displayed DNMT3a and TET2 overexpression, which were insensitive to sorafenib. Either genetic or pharmacological suppression of DNMT3a or\/and TET2 impaired resistant cell growth and oncosphere formation, and restored sorafenib sensitivity. Mechanistically, DNMT3a did not establish a regulatory circuit with TET2, but formed a complex with TET2 and HDAC2. This complex bound the promoters of oncogenes (i.e., CDK1, CCNA2, RASEF), and upregulated them without involving promoter DNA methylation. In contrast, DNMT3a-TET2 crosstalk silences tumor suppressors (i.e., P15, SOCS2) through a corepressor complex with HDAC2 along with increased promoter DNA methylation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We demonstrate that DNMT3a and TET2 act coordinately to regulate HCC cell fate in DNA methylation-dependent and -independent manners, representing strong predictors for drug resistance and poor prognosis, and thus are promising therapeutic targets for refractory HCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12935-024-03288-3","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T06:01:45Z","timestamp":1711346505000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Coordinated activation of DNMT3a and TET2 in cancer stem cell-like cells initiates and sustains drug resistance in hepatocellular carcinoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Tao","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changli","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sicheng","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Sobeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,25]]},"reference":[{"key":"3288_CR1","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","volume":"2","author":"JM Llovet","year":"2016","unstructured":"Llovet JM, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. https:\/\/doi.org\/10.1038\/nrdp.2016.18.","journal-title":"Nat Rev Dis Primers"},{"key":"3288_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ejmech.2017.07.062","volume":"142","author":"GL Beretta","year":"2017","unstructured":"Beretta GL, Cassinelli G, Pennati M, Zuco V, Gatti L. Overcoming ABC transporter-mediated multidrug resistance: the dual role of tyrosine kinase inhibitors as multitargeting agents. Eur J Med Chem. 2017;142:271\u201389. https:\/\/doi.org\/10.1016\/j.ejmech.2017.07.062.","journal-title":"Eur J Med Chem"},{"key":"3288_CR3","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.7150\/thno.41616","volume":"10","author":"J Tang","year":"2020","unstructured":"Tang J, et al. Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma. Theranostics. 2020;10:5384\u201397. https:\/\/doi.org\/10.7150\/thno.41616.","journal-title":"Theranostics"},{"key":"3288_CR4","doi-asserted-by":"publisher","first-page":"7207","DOI":"10.18632\/oncotarget.6889","volume":"7","author":"T Tomonari","year":"2016","unstructured":"Tomonari T, et al. MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma. Oncotarget. 2016;7:7207\u201315. https:\/\/doi.org\/10.18632\/oncotarget.6889.","journal-title":"Oncotarget"},{"key":"3288_CR5","doi-asserted-by":"publisher","unstructured":"Cabral LKD, Tiribelli C, Sukowati CHC. Sorafenib Resistance in Hepatocellular Carcinoma: the relevance of genetic heterogeneity. Cancers (Basel). 2020;12. https:\/\/doi.org\/10.3390\/cancers12061576.","DOI":"10.3390\/cancers12061576"},{"key":"3288_CR6","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nrm2640","volume":"10","author":"AV Probst","year":"2009","unstructured":"Probst AV, Dunleavy E, Almouzni G. Epigenetic inheritance during the cell cycle. Nat Rev Mol Cell Biol. 2009;10:192\u2013206. https:\/\/doi.org\/10.1038\/nrm2640.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3288_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/s0092-8674(00)81656-6","volume":"99","author":"M Okano","year":"1999","unstructured":"Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99:247\u201357. https:\/\/doi.org\/10.1016\/s0092-8674(00)81656-6.","journal-title":"Cell"},{"key":"3288_CR8","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrg.2017.33","volume":"18","author":"X Wu","year":"2017","unstructured":"Wu X, Zhang Y, TET-mediated active. DNA demethylation: mechanism, function and beyond. Nat Rev Genet. 2017;18:517\u201334. https:\/\/doi.org\/10.1038\/nrg.2017.33.","journal-title":"Nat Rev Genet"},{"key":"3288_CR9","doi-asserted-by":"publisher","first-page":"18480","DOI":"10.1074\/jbc.M114.633693","volume":"290","author":"F Yan","year":"2015","unstructured":"Yan F, et al. The DNA methyltransferase DNMT1 and tyrosine-protein kinase KIT cooperatively promote resistance to 5-Aza-2\u2019-deoxycytidine (decitabine) and midostaurin (PKC412) in Lung Cancer cells. J Biol Chem. 2015;290:18480\u201394. https:\/\/doi.org\/10.1074\/jbc.M114.633693.","journal-title":"J Biol Chem"},{"key":"3288_CR10","doi-asserted-by":"publisher","first-page":"6254","DOI":"10.1158\/1078-0432.CCR-17-0235","volume":"23","author":"N Shen","year":"2017","unstructured":"Shen N, et al. Inactivation of receptor tyrosine kinases reverts aberrant DNA methylation in Acute myeloid leukemia. Clin Cancer Res. 2017;23:6254\u201366. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0235.","journal-title":"Clin Cancer Res"},{"key":"3288_CR11","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nature09586","volume":"468","author":"M Ko","year":"2010","unstructured":"Ko M, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010;468:839\u201343. https:\/\/doi.org\/10.1038\/nature09586.","journal-title":"Nature"},{"key":"3288_CR12","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","volume":"363","author":"TJ Ley","year":"2010","unstructured":"Ley TJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363:2424\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1005143.","journal-title":"N Engl J Med"},{"key":"3288_CR13","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.yexcr.2018.01.011","volume":"363","author":"G Yang","year":"2018","unstructured":"Yang G, Zeng X, Wang M, Wu A. The TET2\/E-cadherin\/beta-catenin regulatory loop confers growth and invasion in hepatocellular carcinoma cells. Exp Cell Res. 2018;363:218\u201326. https:\/\/doi.org\/10.1016\/j.yexcr.2018.01.011.","journal-title":"Exp Cell Res"},{"key":"3288_CR14","doi-asserted-by":"publisher","first-page":"11994","DOI":"10.1073\/pnas.1310656110","volume":"110","author":"H Huang","year":"2013","unstructured":"Huang H, et al. TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci U S A. 2013;110:11994\u20139. https:\/\/doi.org\/10.1073\/pnas.1310656110.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3288_CR15","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.1158\/0008-5472.CAN-17-2082","volume":"78","author":"CR Good","year":"2018","unstructured":"Good CR, et al. TET1-Mediated hypomethylation activates Oncogenic Signaling in Triple-negative breast Cancer. Cancer Res. 2018;78:4126\u201337. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-2082.","journal-title":"Cancer Res"},{"key":"3288_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/hep.23660","volume":"52","author":"J Huang","year":"2010","unstructured":"Huang J, Wang Y, Guo Y, Sun S. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology. 2010;52:60\u201370. https:\/\/doi.org\/10.1002\/hep.23660.","journal-title":"Hepatology"},{"key":"3288_CR17","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.it.2019.02.004","volume":"40","author":"AA Emran","year":"2019","unstructured":"Emran AA, et al. Targeting DNA methylation and EZH2 activity to overcome Melanoma Resistance to Immunotherapy. Trends Immunol. 2019;40:328\u201344. https:\/\/doi.org\/10.1016\/j.it.2019.02.004.","journal-title":"Trends Immunol"},{"key":"3288_CR18","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/leu.2017.307","volume":"32","author":"F Yan","year":"2018","unstructured":"Yan F, et al. A vicious loop of fatty acid-binding protein 4 and DNA methyltransferase 1 promotes acute myeloid leukemia and acts as a therapeutic target. Leukemia. 2018;32:865\u201373. https:\/\/doi.org\/10.1038\/leu.2017.307.","journal-title":"Leukemia"},{"key":"3288_CR19","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1038\/leu.2015.56","volume":"29","author":"XN Gao","year":"2015","unstructured":"Gao XN, et al. AML1\/ETO cooperates with HIF1alpha to promote leukemogenesis through DNMT3a transactivation. Leukemia. 2015;29:1730\u201340. https:\/\/doi.org\/10.1038\/leu.2015.56.","journal-title":"Leukemia"},{"key":"3288_CR20","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/s41422-018-0097-4","volume":"28","author":"F Yan","year":"2018","unstructured":"Yan F, et al. A dynamic N(6)-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors. Cell Res. 2018;28:1062\u201376. https:\/\/doi.org\/10.1038\/s41422-018-0097-4.","journal-title":"Cell Res"},{"key":"3288_CR21","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.1038\/s41467-019-12960-6","volume":"10","author":"L Dou","year":"2019","unstructured":"Dou L, et al. Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia. Nat Commun. 2019;10:5051. https:\/\/doi.org\/10.1038\/s41467-019-12960-6.","journal-title":"Nat Commun"},{"key":"3288_CR22","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.2001.19.5.1485","volume":"19","author":"DJ Propper","year":"2001","unstructured":"Propper DJ, et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol. 2001;19:1485\u201392.","journal-title":"J Clin Oncol"},{"key":"3288_CR23","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1182\/blood.V100.8.2957","volume":"100","author":"M Daskalakis","year":"2002","unstructured":"Daskalakis M, et al. Demethylation of a hypermethylated P15\/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2\u2019-deoxycytidine (decitabine) treatment. Blood. 2002;100:2957\u201364. https:\/\/doi.org\/10.1182\/blood.V100.8.2957.","journal-title":"Blood"},{"key":"3288_CR24","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.tibs.2014.05.002","volume":"39","author":"A Jeltsch","year":"2014","unstructured":"Jeltsch A, Jurkowska RZ. New concepts in DNA methylation. Trends Biochem Sci. 2014;39:310\u20138. https:\/\/doi.org\/10.1016\/j.tibs.2014.05.002.","journal-title":"Trends Biochem Sci"},{"key":"3288_CR25","doi-asserted-by":"publisher","first-page":"6919","DOI":"10.1038\/onc.2017.305","volume":"36","author":"F Yan","year":"2017","unstructured":"Yan F, et al. A regulatory circuit composed of DNA methyltransferases and receptor tyrosine kinases controls lung cancer cell aggressiveness. Oncogene. 2017;36:6919\u201328. https:\/\/doi.org\/10.1038\/onc.2017.305.","journal-title":"Oncogene"},{"key":"3288_CR26","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.cell.2011.03.022","volume":"145","author":"JU Guo","year":"2011","unstructured":"Guo JU, Su Y, Zhong C, Ming GL, Song H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell. 2011;145:423\u201334. https:\/\/doi.org\/10.1016\/j.cell.2011.03.022.","journal-title":"Cell"},{"key":"3288_CR27","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nature12750","volume":"502","author":"RM Kohli","year":"2013","unstructured":"Kohli RM, Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature. 2013;502:472\u20139. https:\/\/doi.org\/10.1038\/nature12750.","journal-title":"Nature"},{"key":"3288_CR28","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.4161\/cc.10.16.17093","volume":"10","author":"JU Guo","year":"2011","unstructured":"Guo JU, Su Y, Zhong C, Ming GL, Song H. Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA demethylation and beyond. Cell Cycle. 2011;10:2662\u20138. https:\/\/doi.org\/10.4161\/cc.10.16.17093.","journal-title":"Cell Cycle"},{"key":"3288_CR29","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1021\/acsmedchemlett.8b00474","volume":"10","author":"GNL Chua","year":"2019","unstructured":"Chua GNL, et al. Cytosine-based TET enzyme inhibitors. ACS Med Chem Lett. 2019;10:180\u20135. https:\/\/doi.org\/10.1021\/acsmedchemlett.8b00474.","journal-title":"ACS Med Chem Lett"},{"key":"3288_CR30","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nature15252","volume":"525","author":"Q Zhang","year":"2015","unstructured":"Zhang Q, et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature. 2015;525:389\u201393. https:\/\/doi.org\/10.1038\/nature15252.","journal-title":"Nature"},{"key":"3288_CR31","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.celrep.2015.10.031","volume":"13","author":"P Ma","year":"2015","unstructured":"Ma P, de Waal E, Weaver JR, Bartolomei MS, Schultz RM. A DNMT3A2-HDAC2 complex is essential for genomic imprinting and Genome Integrity in Mouse oocytes. Cell Rep. 2015;13:1552\u201360. https:\/\/doi.org\/10.1016\/j.celrep.2015.10.031.","journal-title":"Cell Rep"},{"key":"3288_CR32","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ng.3610","volume":"48","author":"X Zhang","year":"2016","unstructured":"Zhang X, et al. DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells. Nat Genet. 2016;48:1014\u201323. https:\/\/doi.org\/10.1038\/ng.3610.","journal-title":"Nat Genet"},{"key":"3288_CR33","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.1038\/onc.2014.472","volume":"34","author":"SL Haney","year":"2015","unstructured":"Haney SL, et al. Methylation-independent repression of Dnmt3b contributes to oncogenic activity of Dnmt3a in mouse MYC-induced T-cell lymphomagenesis. Oncogene. 2015;34:5436\u201346. https:\/\/doi.org\/10.1038\/onc.2014.472.","journal-title":"Oncogene"},{"key":"3288_CR34","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.molcel.2016.12.013","volume":"65","author":"YW Zhang","year":"2017","unstructured":"Zhang YW, et al. Acetylation enhances TET2 function in protecting against abnormal DNA methylation during oxidative stress. Mol Cell. 2017;65:323\u201335. https:\/\/doi.org\/10.1016\/j.molcel.2016.12.013.","journal-title":"Mol Cell"},{"key":"3288_CR35","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1593\/neo.10804","volume":"12","author":"TC Tang","year":"2010","unstructured":"Tang TC, et al. Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia. 2010;12:928\u201340. https:\/\/doi.org\/10.1593\/neo.10804.","journal-title":"Neoplasia"},{"key":"3288_CR36","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41586-019-1198-z","volume":"569","author":"F Gaiti","year":"2019","unstructured":"Gaiti F, et al. Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia. Nature. 2019;569:576\u201380. https:\/\/doi.org\/10.1038\/s41586-019-1198-z.","journal-title":"Nature"},{"key":"3288_CR37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma SV, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141:69\u201380. https:\/\/doi.org\/10.1016\/j.cell.2010.02.027.","journal-title":"Cell"},{"key":"3288_CR38","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/ng.2913","volume":"46","author":"B Knoechel","year":"2014","unstructured":"Knoechel B, et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat Genet. 2014;46:364\u201370. https:\/\/doi.org\/10.1038\/ng.2913.","journal-title":"Nat Genet"},{"key":"3288_CR39","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nm.4040","volume":"22","author":"AN Hata","year":"2016","unstructured":"Hata AN, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016;22:262\u20139. https:\/\/doi.org\/10.1038\/nm.4040.","journal-title":"Nat Med"},{"key":"3288_CR40","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1158\/0008-5472.CAN-14-3687","volume":"75","author":"EA Kuczynski","year":"2015","unstructured":"Kuczynski EA, Lee CR, Man S, Chen E, Kerbel RS. Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma. Cancer Res. 2015;75:2510\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-3687.","journal-title":"Cancer Res"},{"key":"3288_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1182","author":"J Yu","year":"2017","unstructured":"Yu J, et al. Dynamic m6A modification regulates local translation of mRNA in axons. Nucleic Acids Res. 2017. https:\/\/doi.org\/10.1093\/nar\/gkx1182.","journal-title":"Nucleic Acids Res"},{"key":"3288_CR42","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.tig.2012.11.003","volume":"29","author":"G Jia","year":"2013","unstructured":"Jia G, Fu Y, He C. Reversible RNA adenosine methylation in biological regulation. Trends Genet. 2013;29:108\u201315. https:\/\/doi.org\/10.1016\/j.tig.2012.11.003.","journal-title":"Trends Genet"},{"key":"3288_CR43","first-page":"65","volume":"20","author":"BK Oh","year":"2007","unstructured":"Oh BK, et al. DNA methyltransferase expression and DNA methylation in human hepatocellular carcinoma and their clinicopathological correlation. Int J Mol Med. 2007;20:65\u201373.","journal-title":"Int J Mol Med"},{"key":"3288_CR44","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3892\/or.2017.5722","volume":"38","author":"J Liu","year":"2017","unstructured":"Liu J, Liu Y, Meng L, Liu K, Ji B. Targeting the PD-L1\/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma. Oncol Rep. 2017;38:899\u2013907. https:\/\/doi.org\/10.3892\/or.2017.5722.","journal-title":"Oncol Rep"},{"key":"3288_CR45","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/leu.2011.326","volume":"26","author":"S Weissmann","year":"2012","unstructured":"Weissmann S, et al. Landscape of TET2 mutations in acute myeloid leukemia. Leukemia. 2012;26:934\u201342. https:\/\/doi.org\/10.1038\/leu.2011.326.","journal-title":"Leukemia"},{"key":"3288_CR46","first-page":"912","volume":"12","author":"Y He","year":"2020","unstructured":"He Y, et al. Role of m(5)C-related regulatory genes in the diagnosis and prognosis of hepatocellular carcinoma. Am J Transl Res. 2020;12:912\u201322.","journal-title":"Am J Transl Res"},{"key":"3288_CR47","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1182\/blood-2012-07-444729","volume":"121","author":"Y Li","year":"2013","unstructured":"Li Y, et al. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN\/PI3K signal pathway. Blood. 2013;121:499\u2013509. https:\/\/doi.org\/10.1182\/blood-2012-07-444729.","journal-title":"Blood"},{"key":"3288_CR48","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1093\/emboj\/20.10.2536","volume":"20","author":"F Fuks","year":"2001","unstructured":"Fuks F, Burgers WA, Godin N, Kasai M, Kouzarides T. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J. 2001;20:2536\u201344. https:\/\/doi.org\/10.1093\/emboj\/20.10.2536.","journal-title":"EMBO J"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-024-03288-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-024-03288-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-024-03288-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T06:17:22Z","timestamp":1711347442000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-024-03288-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,25]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3288"],"URL":"https:\/\/doi.org\/10.1186\/s12935-024-03288-3","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,25]]},"assertion":[{"value":"10 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"110"}}